Marsh & McLennan Companies, Inc. (MRSH) stands as a global leader in professional services, focusing on risk, strategy, and people solutions. The company primarily drives its business through the Risk and Insurance Services segment, which encompasses insurance brokerage via Marsh and reinsurance through Guy Carpenter. Its Consulting segment complements this with health, wealth, and career advice from Mercer, plus strategic consulting from Oliver Wyman. Employing over 95,000 people worldwide, MRSH benefits from strong client retention and a fee-based revenue model linked to insurance premiums and advisory fees. That said, its sensitivity to insurance pricing cycles and interest-rate-driven fiduciary income has left it exposed to recent pressures from falling rates and yields, even with solid underlying fundamentals.
In the last 30 days, MRSH shares have fallen about -9%, closing at 169.17 on March 27, 2026, down from around 186 in late February. The move has been volatile, with a clear downward trend as the stock broke below its 50-day moving average of 179.12, accelerating alongside broader sector weakness.
Looking at the past quarter, the stock dropped -7% to -10% from roughly 185 in late December 2025. It stayed range-bound after earnings at first but then declined steadily, now trading well under the 200-day moving average of 192.84. This reflects ongoing bearish momentum within a 52-week range of 164.89-248.00.
From what I see, the -9% drop in MRSH over the past 30 days largely stems from a sector selloff fueled by concerns over AI disrupting white-collar roles, particularly in insurance brokerage. Headlines such as "The Latest AI Selloff: Insurance Brokers" captured these worries, spiking volatility. Analyst moves added to the strain: Mizuho downgraded MRSH to Neutral from Outperform on February 27, and Barclays slightly cut its price target on March 11, noting overblown AI fears but maintaining caution. Middle East geopolitical tensions brought extra macro uncertainty, hitting financial stocks hard and reinforcing the downtrend. Institutional selling piled on as well.
I also checked this using Tickeron’s AI Screener to gauge how MRSH stacks up against industry peers amid these pressures.
Over the quarter, MRSH's -7% to -10% decline was driven by insurance sector cycles, marked by six straight quarters of falling global commercial rates—down 4% in Q4 2025 due to more capacity and competition. Fiduciary interest income dropped $20 million year-over-year in Q4 from lower rates, with Q1 guidance at $83 million. Even with solid Q4 earnings on January 29—EPS of $2.12 beating expectations and revenue up 9%—the stock went flat at first and then slid further on softening reinsurance pricing and economic clouds. Institutional flows were mixed, but macro factors like rate cuts and AI concerns had the biggest impact, driving shares toward 52-week lows.
One tool I rely on in my analysis is Tickeron’s Trending AI Robots. This page highlights the platform's top-performing AI trading bots out of hundreds that trade thousands of tickers across markets. It curates the best based on recent metrics like win rates, average returns, and consistency for day trading, swing trading, or longer holds. You'll find strategies from momentum and mean reversion to sector-focused plays, complete with drawdowns, Sharpe ratios, and backtests. It's particularly useful for matching bots to your risk profile and goals—I've used it to spot relevant patterns in financial services stocks like MRSH. Check the real-time rankings to enhance your data-driven approach.
I'm watching upcoming Q1 2026 earnings closely for insights into revenue growth, margin gains from the Thrive efficiency program, and fiduciary interest income trends tied to rate paths. Keep an eye on global insurance rates, as further softening could squeeze brokerage commissions. AI adoption risks in insurance, plus potential regulations, deserve attention too. Broader macros—geopolitical stability, inflation, and risk management demand—will shape sentiment. Track institutional flows, analyst updates (Hold consensus with $207+ targets), and reinsurance competition. Potential boosts include Mercer's AltamarCAM acquisition and shifts in M&A transactional risk markets.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
MRSH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where MRSH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on MRSH as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRSH just turned positive on June 04, 2026. Looking at past instances where MRSH's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSH advanced for three days, in of 353 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
MRSH moved below its 50-day moving average on June 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MRSH entered a downward trend on June 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRSH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.516) is normal, around the industry mean (6.462). P/E Ratio (20.847) is within average values for comparable stocks, (27.400). Projected Growth (PEG Ratio) (1.628) is also within normal values, averaging (1.616). Dividend Yield (0.022) settles around the average of (0.016) among similar stocks. P/S Ratio (2.981) is also within normal values, averaging (2.974).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows